Palonosetron is a selective antagonist of 5-HT3 receptor with strong affinity, and has no affinity or low affinity for other receptors. The 5-HT3 receptor is located in the central and peripheral vagus nerve endings of the emetic and chemotherapy sensing area in the last area of the medulla oblongata. Chemotherapeutic drugs stimulate small intestinal chromaffin cells to release 5-HT, which reactivates the 5-HT3 receptor of vagal afferent nerve to produce vomiting reflex.
· Prevent acute nausea and vomiting caused by severe emetic chemotherapy.
· Prevent nausea and vomiting caused by moderate emetic chemotherapy.
According to foreign clinical research reports, 1374 adult patients participated in the clinical study of palonosetron in preventing nausea and vomiting caused by moderate or high emetic chemotherapy. The results showed that the incidence and severity of adverse reactions caused by palonosetron were similar to ondansetron or dorasetron.
It is prohibited to use in patients who are known to be allergic to the drug or any component of the drug.
Synonymous: | Benz[De]Isoquinolin-1-One Hydrochloride |
CAS: | 135729-62-3 |
Molecular Formula: | C19H25ClN2O |
Molecular Weight: | 332.868 |
Appearance: | White powder |
Storage: | Store at room temperature (10 ~ 30 ℃) in a closed manner, away from light and antifreeze |
Category: | For chemotherapy-induced vomiting inhibitors |